A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain

Bibliography

• De Vries HE, Kuiper J, De Boer AG, et al. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 1997;49(2):143-55
   PubMed Web of Science ®Google Scholar
• Barling RW, Selkon JB. The penetration of antibiotics into cerebrospinal fluid and brain tissue. J Antimicrob Chemother 1978;4(3):203-27
   PubMed Web of Science ®Google Scholar
• Dacey RG, Sande MA. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974;6(4):437-41
   PubMed Web of Science ®Google Scholar
• Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Neurol Clin 1999;17(4):883-900
   PubMed Web of Science ®Google Scholar
• Pappenheimer JR, Heisey SR, Jordan EF. Active transport of Diodrast and phenolsulfonphthalein from cerebrospinal fluid to blood. Am J Physiol 1961;200:1-10
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993;62:385-427
   PubMed Web of Science ®Google Scholar
• Beaulieu E, Demeule M, Ghitescu L, et al. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997;326(Pt 2):539-44
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86(2):695-8
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJ, Van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77(4):491-502
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Van Deemter L, et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96(4):1698-705
   PubMed Web of Science ®Google Scholar
• Place VA, Pyle MM, De La Huerga J. Ethambutol in tuberculous meningitis. Am Rev Respir Dis 1969;99(5):783-5
   PubMedGoogle Scholar
• Sippel JE, Mikhail IA, Girgis NI, et al. Rifampin concentrations in cerebrospinal fluid of patients with tuberculous meningitis. Am Rev Respir Dis 1974;109(5):579-80
   PubMedGoogle Scholar
• Hartkoorn RC, Chandler B, Owen A, et al. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis Edinb 2007;87(3):248-55
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;372:159-64
   Google Scholar
• Oldendorf WH. Blood-brain barrier permeabilty to drugs. Ann Rev Pharmacol 1974;14:239-48
   Google Scholar
• Graff CL, Pollack GM. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 2004;5(1):95-108
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2005;2(1):73-85
   PubMedGoogle Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455(1):152-62
   PubMed Web of Science ®Google Scholar
• Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci 2006;256(5):281-6
   PubMed Web of Science ®Google Scholar
• Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997;143(2):357-65
   PubMed Web of Science ®Google Scholar
• Umbenhauer DR, Lankas GR, Pippert TR, et al. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 1997;146(1):88-94
   PubMed Web of Science ®Google Scholar
• Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dis 2000;28(6):655-60
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57(2):203-9
   PubMed Web of Science ®Google Scholar
• Luurtsema G, Molthoff CF, Windhorst AD, et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nulc Med Biol 2003;30(7):747-51
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97(11):2517-24
   PubMed Web of Science ®Google Scholar
• Van Asperen J, Schinkel AH, Beijnen JH, et al. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 1996;88(14):994-9
   PubMed Web of Science ®Google Scholar
• King M, Su W, Chang A, et al. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci 2001;4(3):268-74
   PubMed Web of Science ®Google Scholar
• Mealey KL, Greene S, Bagley R, et al. P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model. Drug Metab Dispos 2008;36(6):1073-9
   PubMed Web of Science ®Google Scholar
• Mealey KL, Bentjen SA, Gay JM, et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001;11(8):727-33
   PubMedGoogle Scholar
• Sartor LL, Bentjen SA, Trepanier L, et al. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J Vet Intern Med 2004;18(1):117-8
   PubMed Web of Science ®Google Scholar
• Loscher W. Drug transporters in the epileptic brain. Epilepsia 2007;48(Suppl 1):8-13
   PubMed Web of Science ®Google Scholar
• Greenberg ML, Fisher PG, Freeman C, et al. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer 2005;45(5):644-8
   PubMed Web of Science ®Google Scholar
• Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000;68(3):231-7
   PubMed Web of Science ®Google Scholar
• Segal MB. The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell Mol Neurobiol 2000;20(2):183-96
   PubMed Web of Science ®Google Scholar
• Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999;96(7):3900-5
   PubMed Web of Science ®Google Scholar
• Gazzin S, Strazielle N, Schmitt C, et al. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 2008;510(5):497-507
   PubMed Web of Science ®Google Scholar
• Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 2005;53(4):517-31
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Golden PL, Kang YS, et al. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 1997;68(3):1278-85
   PubMed Web of Science ®Google Scholar
• Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36(2-3):179-94
   PubMed Web of Science ®Google Scholar
• Bendayan R, Ronaldson PT, Gingras D, et al. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 2006;54(10):1159-67
   PubMed Web of Science ®Google Scholar
• Schlachetzki F, Pardridge WM. P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport 2003;14(16):2041-6
   PubMed Web of Science ®Google Scholar
• Virgintino D, Robertson D, Errede M, et al. Expression of P-glycoprotein in human cerebral cortex microvessels. J Histochem Cytochem 2002;50(12):1671-6
   PubMed Web of Science ®Google Scholar
• Lazarowski A, Caltana L, Merelli A, et al. Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci 2007;258(1-2):84-92
   PubMed Web of Science ®Google Scholar
• Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB J 2001;151:155-63
   Google Scholar
• Nadeau S, Rivest S. Endotoxemia prevents the cerebral inflammatory wave induced by intraparenchymal lipopolysaccharide injection: role of glucocorticoids and CD14. J Immunol 2002;169(6):3370-81
   PubMed Web of Science ®Google Scholar
• Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev 2002;3(3):216-27
   Google Scholar
• Beutler B, Hoebe K, Du X, et al. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003;74(4):479-85
   PubMed Web of Science ®Google Scholar
• Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274(16):10689-92
   PubMed Web of Science ®Google Scholar
• Imbert F, Jardin M, Fernandez C, et al. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. Drug Metab Dispos 2003;31(3):319-25
   PubMed Web of Science ®Google Scholar
• Miyama T, Takanaga H, Matsuo H, et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 1998;42(7):1738-44
   PubMed Web of Science ®Google Scholar
• Scheld WM, Koedel U, Nathan B, et al. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 2002;186(Suppl 2):S225-33
   PubMed Web of Science ®Google Scholar
• Renton KW, Nicholson TE. Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharide-evoked localized inflammation in brain. J Pharmacol Exp Ther 2000;294(2):524-30
   PubMed Web of Science ®Google Scholar
• Nicholson TE, Renton KW. Role of cytokines in the lipopolysaccharide-evoked depression of cytochrome P450 in the brain and liver. Biochem Pharmacol 2001;62(12):1709-17
   PubMed Web of Science ®Google Scholar
• Goralski KB, Hartmann G, Piquette-Miller M, et al. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 2003;139(1):35-48
   PubMed Web of Science ®Google Scholar
• Goralski KB, Abdulla D, Sinal CJ, et al. Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS inflammation. Am J Physiol 2005;289(3):G434-43
   PubMed Web of Science ®Google Scholar
• Gao B, Stieger B, Noe B, et al. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 1999;47(10):1255-64
   PubMed Web of Science ®Google Scholar
• Noe B, Hagenbuch B, Stieger B, et al. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 1997;94(19):10346-50
   PubMed Web of Science ®Google Scholar
• Hartz AM, Bauer B, Fricker G, et al. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 2006;69(2):462-70
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36(2):205-16
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (New York, NY) 1998;282(5396):2085-8
   Google Scholar
• Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2007;71(3):667-75
   PubMed Web of Science ®Google Scholar
• Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol 2006;70(3):1087-98
   PubMed Web of Science ®Google Scholar
• Zhao YL, Du J, Kanazawa H, et al. Effect of endotoxin on doxorubicin transport across blood-brain barrier and P-glycoprotein function in mice. Eur J Pharmacol 2002;445(1-2):115-23
   PubMed Web of Science ®Google Scholar
• Zhao YL, Du J, Kanazawa H, et al. Shiga-like toxin II modifies brain distribution of a P-glycoprotein substrate, doxorubicin, and P-glycoprotein expression in mice. Brain Res 2002;956(2):246-53
   PubMed Web of Science ®Google Scholar
• Wang JH, Scollard DA, Teng S, et al. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J Nucl Med 2005;46(9):1537-45
   PubMed Web of Science ®Google Scholar
• Seelbach MJ, Brooks TA, Egleton RD, et al. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem 2007;102(5):1677-90
   PubMed Web of Science ®Google Scholar
• Hartz AM, Bauer B, Fricker G, et al. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 2004;66(3):387-94
   PubMed Web of Science ®Google Scholar
• Nie XJ, Olsson Y. Endothelin peptides in brain diseases. Rev Neurosci 1996;7(3):177-86
   PubMed Web of Science ®Google Scholar
• Yu C, Kastin AJ, Tu H, et al. TNF activates P-glycoprotein in cerebral microvascular endothelial cells. Cell Physiol Biochem 2007;20(6):853-8
   PubMed Web of Science ®Google Scholar
• Theron D, Barraud De Lagerie S, Tardivel S, et al. Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochem Pharmacol 2003;66(4):579-87
   PubMed Web of Science ®Google Scholar
• Veszelka S, Pasztoi M, Farkas AE, et al. Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem Int 2007;50(1):219-28
   PubMed Web of Science ®Google Scholar
• Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 2008;60(2):196-209
   PubMed Web of Science ®Google Scholar
• Hartz AM, Bauer B, Block ML, et al. Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. FASEB J 2008;22(8):2723-33
   PubMed Web of Science ®Google Scholar
• Hembury A, Mabondzo A. Endothelin-1 reduces P-glycoprotein transport activity in an in vitro model of human adult blood-brain barrier. Cell Mol Neurobiol 2008. [Epub ahead of print]
   PubMedGoogle Scholar
• Langford D, Grigorian A, Hurford R, et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004;63(10):1038-47
   PubMed Web of Science ®Google Scholar
• Nath A, Schiess N, Venkatesan A, et al. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry (Abingdon, England) 2008;20(1):25-31
   PubMed Web of Science ®Google Scholar
• Ghafouri M, Amini S, Khalili K, et al. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006;3:28
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101(2):289-94
   PubMed Web of Science ®Google Scholar
• Hayashi K, Pu H, Tian J, et al. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem 2005;93(5):1231-41
   PubMed Web of Science ®Google Scholar
• Sharp FR, Bergeron M, Bernaudin M. Hypoxia-inducible factor in brain. Adv Exp Med Biol 2001;502:273-91
   PubMed Web of Science ®Google Scholar
• Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87(1):315-424
   PubMed Web of Science ®Google Scholar
• Rodriguez-Yanez M, Castillo J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol 2008;21(3):353-7
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62(12):3387-94
   PubMed Web of Science ®Google Scholar
• Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 2000;3(2):268-80
   PubMed Web of Science ®Google Scholar
• Yu XY, Lin SG, Chen X, et al. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Curr Drug Metab 2007;8(4):365-78
   PubMed Web of Science ®Google Scholar
• Chen X, Zhou ZW, Xue CC, et al. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica 2007;37(6):635-78
   PubMed Web of Science ®Google Scholar
• Spudich A, Kilic E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 2006;9(4):487-8
   PubMed Web of Science ®Google Scholar
• Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005;115(11):3285-90
   PubMed Web of Science ®Google Scholar
• Vogelgesang S, Warzok RW, Cascorbi I, et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004;1(2):121-5
   PubMed Web of Science ®Google Scholar
• Eikelenboom P, Bate C, Van Gool WA, et al. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002;40(2):232-9
   PubMed Web of Science ®Google Scholar
• Kuhnke D, Jedlitschky G, Grube M, et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides – implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain pathol (Zurich, Switzerland) 2007;17(4):347-53
   PubMed Web of Science ®Google Scholar
• Lam FC, Liu R, Lu P, et al. Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001;76(4):1121-8
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003;13(5):259-63
   PubMedGoogle Scholar
• Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002;12(7):529-34
   PubMedGoogle Scholar
• Lee CG, Tang K, Cheung YB, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 2004;41(5):e60
   PubMed Web of Science ®Google Scholar
• Kortekaas R, Leenders KL, Van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57(2):176-9
   PubMed Web of Science ®Google Scholar
• Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007;150(8):963-76
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev 2005;6(8):591-602
   Google Scholar
• Lazarowski A, Czornyj L, Lubienieki F, et al. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007;48(Suppl 5):140-9
   PubMed Web of Science ®Google Scholar
• Van Vliet EA, Van Schaik R, Edelbroek PM, et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007;322(1):141-7
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Pekcec A, et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008;73(5):1444-53
   PubMed Web of Science ®Google Scholar
• De Vries NA, Zhao J, Kroon E, et al. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 2007;13(21):6440-9
   PubMed Web of Science ®Google Scholar
• Balayssac D, Cayre A, Authier N, et al. Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats. Eur J Pharmacol 2006;544(1-3):49-57
   PubMed Web of Science ®Google Scholar
• Hayashi K, Pu H, Andras IE, et al. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 2006;26(8):1052-65
   PubMed Web of Science ®Google Scholar
• Ikoma Y, Takano A, Ito H, et al. Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med 2006;47(9):1531-7
   PubMed Web of Science ®Google Scholar